UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Yu Z
(2022)
Genome-wide pleiotropy analysis of coronary artery disease and pneumonia identifies shared immune pathways.
in Science advances
Yu Z
(2022)
Causal effect of iron status on lung function: A Mendelian randomization study.
in Frontiers in nutrition
Yu Y
(2022)
Sleep Duration and Visceral Adipose Tissue: Linear and Nonlinear Mendelian Randomization Analyses.
in The Journal of clinical endocrinology and metabolism
Yu XH
(2022)
Systematic Evaluation of Rheumatoid Arthritis Risk by Integrating Lifestyle Factors and Genetic Risk Scores.
in Frontiers in immunology
Yu XH
(2021)
Rheumatoid arthritis and osteoporosis: shared genetic effect, pleiotropy and causality.
in Human molecular genetics
Yu XH
(2023)
Body surface area is a potential obesity index: Its genetic determination and its causality for later-life diseases.
in Obesity (Silver Spring, Md.)
Yu XH
(2021)
Birth weight is positively associated with adult osteoporosis risk: observational and Mendelian randomization studies.
in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Yu X
(2022)
A suggested shared aetiology of dementia - a colocalization study
in Neurobiology of Aging
Yu X
(2022)
Systematic evaluation for the causal effects of blood metabolites on osteoporosis: Genetic risk score and Mendelian randomization
in Frontiers in Public Health
Yu X
(2022)
The association between plasma chemokines and breast cancer risk and prognosis: A mendelian randomization study.
in Frontiers in genetics
Yu WY
(2023)
Efficient identification of trait-associated loss-of-function variants in the UK Biobank cohort by exome-sequencing based genotype imputation.
in Genetic epidemiology
Yu M
(2021)
Genome-Wide Association Meta-Analysis Supports Genes Involved in Valve and Cardiac Development to Associate With Mitral Valve Prolapse.
in Circulation. Genomic and precision medicine
Yu K
(2022)
Meta-imputation: An efficient method to combine genotype data after imputation with multiple reference panels.
in American journal of human genetics
Yu K
(2023)
Association of residential greenness with incident chronic obstructive pulmonary disease: A prospective cohort study in the UK Biobank.
in Environment international
Yu H
(2022)
Causal effects of homocysteine levels on the components of sarcopenia: A two-sample mendelian randomization study.
in Frontiers in genetics
Yu E
(2022)
The effects of the interaction of genetic predisposition with lifestyle factors on bladder cancer risk
in BJU International
Yu C
(2020)
Detecting Genotype-Population Interaction Effects by Ancestry Principal Components.
in Frontiers in genetics
Yu B
(2023)
Age-specific and sex-specific associations of visceral adipose tissue mass and fat-to-muscle mass ratio with risk of mortality.
in Journal of cachexia, sarcopenia and muscle
Yousaf A
(2021)
Association Between Alopecia Areata and Natural Hair Color Among White Individuals.
in JAMA dermatology
Young WJ
(2021)
Genetically Determined Serum Calcium Levels and Markers of Ventricular Repolarization: A Mendelian Randomization Study in the UK Biobank.
in Circulation. Genomic and precision medicine
Young M
(2022)
ODP146 Exploring Systemic Inflammation in the Relationships Between Poor Sleep Health or Shift-Work and Blood Pressure Across BMI, Sex and Age Groups
in Journal of the Endocrine Society
Young KG
(2022)
Glycated haemoglobin measurements from UK Biobank are different to those in linked primary care records: implications for combining biochemistry data from research studies and routine clinical care.
in International journal of epidemiology
Young AI
(2022)
Mendelian imputation of parental genotypes improves estimates of direct genetic effects.
in Nature genetics
Young AI
(2018)
Identifying loci affecting trait variability and detecting interactions in genome-wide association studies.
in Nature genetics
You Y
(2023)
Multi-modal machine learning based on electrocardiogram data for prediction of patients with ischemic heart disease
in Electronics Letters
Yoshiji S
(2022)
LBODP001 Causal Associations Between Body Fat Accumulation and Covid-19 Severity: A Mendelian Randomization Study
in Journal of the Endocrine Society
Yoshiji S
(2022)
Causal associations between body fat accumulation and COVID-19 severity: A Mendelian randomization study.
in Frontiers in endocrinology
Yonova-Doing E
(2021)
An atlas of mitochondrial DNA genotype-phenotype associations in the UK Biobank.
in Nature genetics
Yong SY
(2020)
Genetic architecture of complex traits and disease risk predictors.
in Scientific reports
Yin J
(2022)
Association of mood disorder with cardiometabolic multimorbidity trajectory and life expectancy, a prospective cohort study.
in Journal of affective disorders
Yin C
(2023)
Anatomically interpretable deep learning of brain age captures domain-specific cognitive impairment.
in Proceedings of the National Academy of Sciences of the United States of America
Yildirim AM
(2022)
A cross-sectional study of male balding patterns in people of color.
in Journal of the American Academy of Dermatology
Yildirim AM
(2023)
Correlation of rosacea with hot beverage intake.
in Skin health and disease
Yi X
(2022)
Morroniside ameliorates inflammatory skeletal muscle atrophy via inhibiting canonical and non-canonical NF-?B and regulating protein synthesis/degradation.
in Frontiers in pharmacology
Yeung MW
(2022)
Twenty-Five Novel Loci for Carotid Intima-Media Thickness: A Genome-Wide Association Study in >45 000 Individuals and Meta-Analysis of >100 000 Individuals.
in Arteriosclerosis, thrombosis, and vascular biology
Yeung M
(2022)
ukbpheno v1.0: An R package for phenotyping health-related outcomes in the UK Biobank
in STAR Protocols
Yeung H
(2022)
Predicting sex, age, general cognition and mental health with machine learning on brain structural connectomes
in Human Brain Mapping
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 06/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |